Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more

Applications | GMP Transfection for AAV Production

TransIT-VirusGEN® GMP Transfection Reagents and Kits

Nucleic Acid Delivery

  • Achieve higher titers and percent full AAV capsids
  • >50% savings on a cost per dose basis vs. the leading competitor
  • Universally platformable across all AAV serotypes

ISO 13485:2016 Certified

Completion of this comprehensive certification process underscores the quality of the processes used to support the company’s GMP product portfolio

View the certificate

The Highest Quality Grade for Cell & Gene Therapy

VirusGEN® is a proven transfection reagent combining industry-leading yield performance with real world economic
advantages by delivering a reduced cost per dose — all supported by comprehensive expertise for cell and gene therapy.

VirusGEN® specifications support virus production fit-for-purpose requirements.

Designed to be Biomimetic for Optimized Performance

What makes VirusGEN® unique?

  • Mirus proprietary lipid and polymer technology
  • Forms lipopolyplex with DNA (or nucleic acid)
  • Biomimetic behavior increases transfection efficiency


What benefit does this bring?

  • Higher titers vs. PEI (2-10x) and higher percent full AAV capsids


VirusGEN Outperforms Competitor Reagents in Various AAV Serotypes
VirusGEN AAV Transfection Kit Competitor comparison Data

VirusGEN Percent Full Titer Consistently Outperforms CompetitorsVirusGEN-AAV Transfection Kit AAV percent full titer Data

Higher Titers Deliver Significant Cost Per Dose Savings

VirusGEN AAV Transfection Kit Cost per dose comparison Data



Storage Conditions:

VirusGEN® GMP AAV Transfection Kit: Multiple storage conditions – see individual bottles for specific recommendations
TransIT-VirusGEN® GMP Transfection Reagent: Store at -10 to -30°C

Product Guarantee:

All Configurations: Refer to Certificate of Analysis for Retest Date

Usage Statement:

All Configurations: For Research Use and Further Manufacturing; Not for Administration into Humans.

Animal Origin Statement:

All Configurations: This product is animal origin free.


Technical Product Literature

Directly From Our Customers

Listen to the first-hand account of how Mirus helped researchers from St. Jude overcome the challenges with viral vector optimization to produce ground-breaking gene therapy for hemophilia. Go to the podcast >> 

"Mirus sent me samples of TransIT-VirusGEN® to test with 293T cells to generate lentivirus. It outperforms the transfection reagent I was using before. The protocol is really simple, and the transfections are robust. I’m getting great virus production."
Dr. Steve Williams
Xyphos Inc.